Cargando…
The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia
In patients with chronic kidney disease (CKD), adverse outcomes such as systemic inflammation and anemia are contributing pathologies which increase the risks for cardiovascular mortality. Amongst these complications, abnormalities in mineral metabolism and the metabolic milieu are associated with c...
Autores principales: | Czaya, Brian, Faul, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747522/ https://www.ncbi.nlm.nih.gov/pubmed/31461904 http://dx.doi.org/10.3390/ijms20174195 |
Ejemplares similares
-
Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
por: Czaya, Brian, et al.
Publicado: (2022) -
Fibroblast growth factor 23, klotho and heparin
por: Thomas, S. Madison, et al.
Publicado: (2023) -
The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
por: Bielesz, Bernhard, et al.
Publicado: (2020) -
Fibroblast growth factor 23 and bone mineralisation
por: Guo, Yu-Chen, et al.
Publicado: (2015) -
The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
por: Heijboer, Annemieke C., et al.
Publicado: (2022)